Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nventa Biopharmaceuticals has presented promising preclinical data on HSpE7, its investigational therapeutic vaccine for the treatment of human papillomavirus (HPV)-related diseases.
Subscribe to our email newsletter
The data demonstrated greater potency and specific activation of the immune response when HspE7 was combined with either of the two adjuvants studied.
“These data suggest that combining HspE7 with an adjuvant may significantly increase its potential therapeutic effect by increasing the immune response against the E7 HPV protein,” said Dr Peter Emtage, Nventa’s vice president of R&D. “This finding is notable, as we believe HspE7 plus an adjuvant represents a new potential clinical therapeutic approach to treating serious HPV-related diseases.”
Nventa recently announced the completion of a supply agreement for one of the adjuvants used in this study, a compound known as Poly-ICLC or Hiltonol, with which it expects to advance HspE7 into human clinical trials. The compound has been shown to activate innate immunity.
Previous data have shown that an injection of HspE7 results in tumor regression in mice. The study presented today examined the possibility of improving this immune response by adding Poly-ICLC or another adjuvant TLR-9 agonist CpG. The study found that a more robust immune response was generated by combining the adjuvants with HspE7.
Responses measured demonstrated the combination of antigen plus either adjuvant to be far more active and potent compared to the activity of either HspE7 or adjuvant alone.
An estimated 80% of sexually active men and women are infected by genital HPV at some point in their lives